Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

SELL
$6.01 - $11.48 $382,260 - $730,173
-63,604 Reduced 48.11%
68,606 $755,000
Q3 2023

Nov 14, 2023

SELL
$8.24 - $12.97 $444,070 - $698,979
-53,892 Reduced 28.96%
132,210 $1.11 Million
Q2 2023

Aug 14, 2023

BUY
$9.99 - $18.27 $834,184 - $1.53 Million
83,502 Added 81.39%
186,102 $2.34 Million
Q1 2023

May 15, 2023

SELL
$15.0 - $22.76 $80,370 - $121,948
-5,358 Reduced 4.96%
102,600 $1.69 Million
Q4 2022

Feb 14, 2023

SELL
$14.16 - $24.02 $503,557 - $854,199
-35,562 Reduced 24.78%
107,958 $1.61 Million
Q3 2022

Nov 14, 2022

BUY
$18.07 - $31.37 $156,070 - $270,942
8,637 Added 6.4%
143,520 $3.21 Million
Q2 2022

Aug 15, 2022

SELL
$13.31 - $34.88 $1.86 Million - $4.86 Million
-139,400 Reduced 50.82%
134,883 $2.26 Million
Q1 2022

May 16, 2022

SELL
$20.26 - $32.36 $10.6 Million - $16.9 Million
-522,464 Reduced 65.57%
274,283 $8.21 Million
Q4 2021

Feb 14, 2022

BUY
$26.0 - $37.03 $910,104 - $1.3 Million
35,004 Added 4.6%
796,747 $24.5 Million
Q3 2021

Nov 15, 2021

SELL
$29.75 - $37.99 $2.2 Million - $2.8 Million
-73,795 Reduced 8.83%
761,743 $24 Million
Q2 2021

Aug 16, 2021

SELL
$27.5 - $38.19 $32.6 Million - $45.3 Million
-1,184,923 Reduced 58.65%
835,538 $30.6 Million
Q1 2021

May 17, 2021

SELL
$32.52 - $61.53 $1.51 Million - $2.86 Million
-46,470 Reduced 2.25%
2,020,461 $69.8 Million
Q4 2020

Feb 16, 2021

BUY
$35.51 - $54.03 $1.47 Million - $2.24 Million
41,430 Added 2.05%
2,066,931 $85.9 Million
Q3 2020

Nov 16, 2020

BUY
$32.81 - $45.1 $66.5 Million - $91.4 Million
2,025,501 New
2,025,501 $86.3 Million

Others Institutions Holding RLAY

About Relay Therapeutics, Inc.


  • Ticker RLAY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 120,219,000
  • Market Cap $786M
  • Description
  • Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhib...
More about RLAY
Track This Portfolio

Track Gilder Gagnon Howe & CO LLC Portfolio

Follow Gilder Gagnon Howe & CO LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gilder Gagnon Howe & CO LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gilder Gagnon Howe & CO LLC with notifications on news.